Next week, CureSearch for Children’s Cancer is proudly hosting the third annual Catapult Summit, acting as a neutral convener of industry leaders to lead the way for better treatments for childhood cancer patients.
CureSearch is inviting leaders from industry, academia, investment, business, healthcare, our own key advisors and more to this collaborative event. The Catapult Summit will provide an open forum to address the gaps the industry faces and develop an action plan to advance better, less-toxic treatments for children’s cancer.
“We feel honored that the highest-level experts in the pediatric cancer arena are coming together for this Summit,” said Kay Koehler, CureSearch CEO. “Our collective goal is to help children with cancer; the path to that goal is the identification and development of potential solutions to the research, regulatory and commercialization challenges we face in getting drugs to market faster.”
Our research strategy is designed to quickly advance the strongest children’s cancer research and accelerate real treatments to the marketplace for children. As part of our strategy, CureSearch has stepped up to drive the collaborations needed to push forward our mutual goal: to deliver less-toxic treatments to kids now.
“Pediatric cancer drug development is an increasingly dynamic, competitive and challenging environment on all fronts,” said Dr. Sam Blackman, Senior Vice President at Silverback Therapeutics, Chair of our Industry Advisory Council and Summit panel facilitator. “CureSearch occupies a unique position in this ecosystem because of their ability to convene committed and passionate researchers from all areas of expertise.”
This significant strategic meeting will act as an open forum for discussion and provide clear action for moving forward with our research strategy. The goal is to identify obstacles, understand why they are impeding progress and develop ways to drive new therapies for children with cancer.
“Here at Novartis, we are so committed to expedited discovery and development of breakthrough drugs for children with cancer,” said Dr. Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR). “I look forward to sharing our experiences on developing first CAR-T therapy for pediatric ALL, and considering more generally how our community can rally together around the longstanding challenge of undruggable targets in pediatric tumors. Most of all, I look forward to listening – to the great and impassioned leaders assembled by this remarkable organization.”
Learn more about CureSearch’s research strategy and view the below video to learn more about the Catapult Summit.
A special thank you to our generous event sponsors : Jazz Pharmaceuticals, Gilled, Amgen, Bristol-Myers Squibb and initiative sponsors: Genentech, Novartis,
and Acerta Pharma (AstraZeneca Group).
Want more stories like this?
Get emails that matter, when it matters.